Sunflower Pharmaceutical’s drug quality problems were exposed again. Previously, 16 batches of drugs failed to pass the random inspection

On June 20, the State Food and Drug Administration issued a notice that 15 batches of drugs did not meet the regulations. Among them, sunflower pharmaceutical drugs are listed again. It is worth noting that, according to the database of the State Food and Drug Administration, previously, 16 batches of drugs marked with sunflower pharmaceuticals had failed random inspections, involving Yanlixiao Capsules, Anka Huangmin Capsules, Pediatric Huatanzhike Granules, and compound anti-acetylene drugs. Commonly used varieties such as aminophenol tablets.

According to the announcement of the State Food and Drug Administration on June 20, after inspection by the Chongqing Food and Drug Inspection and Testing Institute, it was marked as a batch of apricots produced by Sunflower Pharmaceutical Group (Xiangyang) Longzhong Co., Ltd. entrusted by Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd. Su cough syrup does not meet the requirements, and the item that does not meet the requirements is the pH value.

It is understood that the pH value is an index of hydrogen ion concentration, which is used as a measure of the degree of acidity and alkalinity. If the pH value is unqualified, will the safety and efficacy of the drug be affected? What kind of hidden dangers will patients face after taking it? In addition, where are the sold substandard drugs going? How is the recall going? In this regard, a reporter from China Economic Net called Sunflower Pharmaceutical on the morning of June 21, and told the reporter that they could call again after 14:30, and the company’s representative would reply to the reporter. However, after 14:30, the reporter called Sunflower Pharmaceutical several times, but no one answered the phone.

In fact, in recent years, Sunflower Pharmaceutical has been exposed many times in terms of drug quality issues. A reporter from China Economic Net searched “Sunflower Pharmaceutical” in the database of the State Food and Drug Administration and found that 16 batches of unqualified drugs were listed, involving Yanlixiao Capsules, Wood Beetle Chong, Anka Huangmin Capsules, Chenxianglu Bailu Tablets, Yin There are 7 varieties of Qiaoshangfeng Capsules, Pediatric Huatanzhike Granules, and Compound Paracetamol Tablets.

It is worth noting that among the above-mentioned 16 batches of unqualified drugs, the company involved in the incident, Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd., involved a total of 3 batches of drugs. According to Sunflower Pharmaceutical’s “2022 Annual Report”, Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd. is a wholly-owned subsidiary of Sunflower Pharmaceutical Group (Xiangyang) Longzhong Co., Ltd., and Sunflower Pharmaceutical Group (Xiangyang) Longzhong Co., Ltd. A subsidiary of Sunflower Pharmaceutical Holdings, these two subsidiaries will be recognized as high-tech enterprises in 2022, and enjoy a preferential corporate income tax rate of 15% from 2022 to 2024.

Source link